Groundbreaking research from professionals at Augusta University has revealed that Cannabidiol (CBD) could be integral in helping treat late-stage COVID-19 patients in critical condition. Dr. Jack Yu, chief of pediatric plastic surgery and the Milford B. Hatcher Professor of Surgery at Augusta University and Dr. Babak Baban, an immunologist and interim associate dean for research at Dental College of Georgia have debriefed these recent discoveries in an article published by the Augusta Chronicle on July 15, 2020.
Linked to upward of 18 medical applications, CBD has become a popularized ingredient for users seeking anti-inflammatory effects. Yu and Baban have discovered revolutionary new ways CBD could optimize healing time around wounds which could translate to treating acute respiratory distress syndrome, the late-stage condition of COVID-19. This dangerous stage of the virus accelerates quickly and can be fatal.
Cannabidiol (CBD) and tetrahydrocannabinol (THC) are the two primary cannabinoids, or chemical compounds, naturally occurring in the Cannabis sativa plant. They differ in that THC produces a ‘high’ for the user while CBD does not. Researchers are hoping to continue to study and test CBD as a potential treatment option as it is already approved by the Food and Drug Administration for the treatment of some seizure disorders in children, giving it a “well-established” safety profile according to Dr. Yu. Click to read more about how CBD affects COVID-19 patients.
As a distributor of CBD, Viachem is proud to partner with the largest hemp extraction company in the world, Folium Biosciences, to provide the highest quality CBD-based products in the industry. They produce a superior, premium ingredient that has 0.00 percent THC. Together, we strive to set the highest standard in CBD oil for nutrition products. Learn more about our CBD or purchase a sample, contact our team directly at [email protected].